Future oncology (London, England)HumansCarcinomaNon-Small-Cell LungLung NeoplasmsErbB Receptors
Osimertinib before and after chemoradiotherapy for unresectable stage III EGFR-mutated NSCLC: NEOLA Trial Protocol.
Jacqueline V Aredo, Nir Peled, Edurne Arriola, Heather Wakelee, Myung-Ju Ahn, Margriet H Kwint, Rosemary Taylor, Toon van der Gronde, Feruza Nasirova, Ming Chen
Published: 202510.1080/14796694.2025.2587569
Abstract
Open AccessCLINICAL TRIAL REGISTRATION: ClinicalTrials.gov identifier is NCT06194448 (date of registration 5 January 2024).